Literature DB >> 33344545

Risk factors analysis of prognosis of adult acute severe myocarditis.

Qian Zhang1, Rui Zhao2.   

Abstract

BACKGROUND: Adult severe myocarditis is primarily caused by infection with any number of a variety of viruses. It arises quickly, progresses rapidly, and may lead to severe heart failure or circulatory failure presenting as rapid-onset hypotension and cardiogenic shock with a high hospital mortality rate. AIM: To analyze the risk factors affecting the short-term prognosis of adult acute severe myocarditis (ASM).
METHODS: Adult patients with ASM (ASM group, n = 218) and acute nonsevere myocarditis (ANSM group, n = 80) who came to our department from January 2014 to January 2020 were enrolled in this study. Patients with ASM were divided into the ASM survival group (n = 185) and ASM nonsurvival group (n = 33) according to the treatment results during hospitalization. The clinical symptoms, laboratory examinations, treatment methods, complications, and the relationship between the treatment results of the two groups were retrospectively compared and discussed. The risk factors for death in patients with severe myocarditis were analyzed by binary logistic regression. A follow-up to 5.5 years was conducted on patients in the ASM survival group and ANSM group after discharge, and the readmission rate and incidence rate of dilated cardiomyopathy were analyzed.
RESULTS: Compared with the ASM survival group, the ASM nonsurvival group had longer QRS complex, higher incidence of cardiogenic shock, higher serum creatinine (SCr, 235μmol/L vs 89 μmol/L, P < 0.05), higher sensitive cardiac troponin I (cTnI, 4.45 μg/L vs 1.66 μg/L, P < 0.05) and brain natriuretic peptide (BNP, 1756 pg/mL vs 401 pg/mL, P < 0.05). The binary logistic regression revealed that there were statistical differences between the two groups in SCr, cTnI, and BNP values (all P < 0.05). After discharging from the hospital, patients in the ASM group and ANSM group had no significant differences in the readmission rate and incidence rate of dilated cardiomyopathy.
CONCLUSION: Elevated SCr, cTnI, and BNP are independent predictors for poor prognosis in patients with ASM. The long-term prognosis of patients in the ASM survival group is good. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Acute severe myocarditis; Dilated cardiomyopathy; Hospital mortality; Prognosis; Risk factor

Year:  2020        PMID: 33344545      PMCID: PMC7716313          DOI: 10.12998/wjcc.v8.i22.5547

Source DB:  PubMed          Journal:  World J Clin Cases        ISSN: 2307-8960            Impact factor:   1.337


Core Tip: Elevated serum creatinine, sensitive troponin I, and brain natriuretic peptide are independent predictors for poor prognosis in patients with acute severe myocarditis.

INTRODUCTION

According to the World Health Organization’s classification of cardiomyopathies, myocarditis is clinically and pathologically defined as an inflammatory disease of the myocardium diagnosed by established histological, immunological, and immunohistochemical criteria. The actual incidence of myocarditis is difficult to determine as endomyocardial biopsy (EMB), the diagnostic gold standard, is used infrequently[1]. Studies addressing the issue of sudden cardiac death in young people reported a highly variable autopsy rate ranging from 2% to 42% of cases[2]. Similarly, biopsy-proven myocarditis is reported in 9% to 16% of adult patients with unexplained nonischemic dilated cardiomyopathy (DCM) and 46% of children with identified causes of DCM[3]. Besides, biopsy-proven myocarditis can progress to DCM and is associated with a poor prognosis in up to 30% of cases[4]. In patients presenting mild symptoms and minimal ventricular dysfunction, myocarditis often resolves spontaneously without specific treatment[2]. Nevertheless, in patients with acute severe myocarditis (ASM), which has the characteristics of acute onset, severe illness, and high mortality rate, cardiovascular adverse events such as heart failure, malignant arrhythmia, cardiac arrest, and even sudden death may easily occur. Early identification of patients with a severe tendency is of great significance for selecting treatment strategies and improving the prognosis. This study retrospectively analyzed the data of patients with endocarditis admitted to our department from January 2014 to January 2020. Through the comparison between ASM survival patients and ASM nonsurvival patients and ASM survival patients and acute nonsevere myocarditis (ANSM) patients, we discussed the risk factors for in-hospital death and prognosis in patients with ASM.

MATERIALS AND METHODS

Study population

ASM patients and ANSM patients admitted to our department from January 2014 to January 2020 were enrolled in this study. Inclusion criteria for adult patients with ASM were: (1) Age > 18-years-old; and (2) In accordance with the diagnostic criteria for acute viral myocarditis and accompanied by at least one of the obvious cardiac enlargement, congestive heart failure, cardiogenic shock, severe arrhythmia, increased troponin, galloping horse, or pericardial friction sound, which is consistent with the diagnosis of ASM[5]. Inclusion criteria for patients with ANSM were: (1) 18-75-years-old; and (2) In accordance with the diagnostic criteria of acute viral myocarditis. Exclusion criteria were: (1) < 18- or > 75-years-old; and (2) Complicated by the following diseases: Acute coronary syndrome, chronic cardiac insufficiency NYHA Class III-IV, chronic renal insufficiency class III-V, and stroke. Patients with ASM were divided into the ASM survival group and ASM nonsurvival group according to the treatment results during hospitalization. Patients in the ASM survival group and patients in the ANSM group (control group) were followed up for 0.4-5.5 years.

Methods

This is a retrospective cohort study. The basic characteristics, electrocardiogram (ECG) characteristics, laboratory examinations (taking the peak value of abnormal values), treatment methods, in-hospital complications, length of stay, and other clinical data were recorded. The primary endpoint of this study was in-hospital death. The changes of ST-T segment of ECG (suggesting myocardial ischemia), prolongation of QRS duration (suggesting bundle branch block), left ventricular ejection fraction, left ventricular inner diameter, high-sensitivity cardiac troponin I (cTnI, normal value < 3.1 ng/mL), brain natriuretic peptide (BNP, normal value < 100 pg/mL), serum creatinine (SCr, normal value < 100 pg/mL), and major complications (cardiogenic shock, malignant arrhythmia, third-degree atrioventricular block, aspen syndrome, acute renal failure, etc.) were also recorded. Patients were followed up for 0.4-5.5 years after discharge, and the recovery, readmission, and dilated cardiomyopathy were recorded and compared.

Statistical analysis

The data were analyzed by SPSS 25.0 statistical software (SPSS, Inc., Chicago, IL, United States). Continuous variables were presented as mean ± standard deviations and were compared using Student t test as appropriate. Non-normal distribution data were expressed by M (Q1, Q3), and Mann-Whitney U test was used. The comparison between groups was performed by χ test or Fisher’s exact test. The logistic stepwise regression analysis was used to analyze the risk factors for the prognosis of ASM patients. Statistical significance was set at a P value < 0.05.

RESULTS

A total of 265 patients were enrolled in our study, including 185 ASM and 80 ANSM patients. Of all the patients, 64.9% of patients (n = 172) were male with an average age of 39 ± 14-years-old (Table 3). A total of 33 ASM patients (male, n = 20) died in the hospital, with an average age of 40 ± 16-years-old (Table 1).
Table 3

Comparison between acute nonsevere myocarditis group and acute severe myocarditis survival group


ANSM group, n = 80
ASM survival group, n = 185
Total, n = 265
Male, n (%)51 (63.8)121 (65.4)172 (64.9)
Age in yr39 ± 1340 ± 1539 ± 14
QRS duration prolonged, n (%)04 (2.2)4 (1.5)
Low LVEF, n (%)8 (10.0)45 (24.3)53 (0.2)
Left ventricular dilatation, n (%)5 (6.3)43 (23.2)48 (18.1)
cTnI in μg/L0.12 (0.03, 0.61)1.66 (0.25, 6.16)1.19 (0.10, 0.82)
BNP in pg/mL56 (32, 106)401 (69, 1072)78 (41, 437)
SCr in μmol/L65 (43, 80)88 (76, 102)81 (65, 92)
Cardiogenic shock, n (%)2 (2.5)33 (17.8)35 (13.2)
Malignant ventricular arrhythmia, n (%)5 (6.3)31 (16.8)36 (13.6)
Acute renal failure, n (%)2 (2.5)33 (17.8)35 (13.2)
Follow up duration in yr2.4 ± 1.22.7 ± 1.42.6 ± 1.3
Re-hospitalization rate, n (%)2 (7.5)4 (2.2)6 (2.3)
Dilated cardiomyopathy, n (%)4 (5.0)7 (3.8)11 (4.2)

ANSM: Acute nonsevere myocarditis; ASM: Acute severe myocarditis; BNP: Brain natriuretic peptide; cTnI: Cardiac troponin I; LVEF: Left ventricular ejection fraction; SCr: Serum creatinine.

Table 1

Analysis of risk factors for death of acute severe myocarditis patients


ASM survival group, n = 185
ASM nonsurvival group, n = 33
Total, n = 218
P value
Male, n (%)121 (65.4)20 (60.6)141 (64.7)0.415
Age in yr39 ± 1340 ± 1639 ± 140.946
Previous infection, n (%)92 (49.7)15 (45.5)107 (49.1)0.835
Hospitalization duration, d9 ± 76 ± 78 ± 70.165
Changes in ST-T segment, n (%)74 (40.0)14 (42.4)88 (40.4)0.976
QRS duration prolonged, n (%)4 (2.2)12 (36.4)a14 (7.3)0.001a
Low LVEF, n (%)45 (24.3)18 (54.5)63 (28.9)0.481
Left ventricular dilatation, n (%)43 (23.2)15 (45.5)58 (26.6)0.332
cTnI in μg/L1.66 (0.25, 6.16)41.45 (19.65, 48.62)7.67 (1.15, 25.33)0.027a
BNP in pg/mL401 (69, 1073)1756 (1041, 3787)606 (84, 1286)0.001a
SCr in μmol/L89 (76, 102)235 (151, 315)111 (84, 135)0.011a
Cardiogenic shock, n (%)33 (17.8)32 (97.0)a65 (29.8)0.037a
Malignant ventricular arrhythmia, n (%)31 (16.8)17 (51.5)48 (22.0)0.094
Third degree atrioventricular block, n (%)12 (6.5)8 (24.2)20 (9.2)0.079
ASPEN syndrome, n (%)8 (4.3)6 (18.2)14 (6.4)0.618
Acute renal failure, n (%)33 (17.8)13 (39.4)46 (21.1)0.284
Applying methylprednisolone, n (%)76 (41.1)27 (81.8)103 (47.2)0.439
Applying IABP, n (%)13 (7.0)5 (15.2)18 (8.3)0.462
Applying ECMO, n (%)3 (1.6)2 (6.1)5 (2.3)0.651
Temporary pacemaker implantation, n (%)27 (14.6)13 (39.4)40(18.3)0.722

P < 0.05. ASM: Acute severe myocarditis; BNP: Brain natriuretic peptide; cTnI: Cardiac troponin I; ECMO: Extracorporeal membrane oxygenation; IABP: Intra-aortic balloon pump; LVEF: Left ventricular ejection fraction; SCr: Serum creatinine.

Analysis of risk factors for death of acute severe myocarditis patients P < 0.05. ASM: Acute severe myocarditis; BNP: Brain natriuretic peptide; cTnI: Cardiac troponin I; ECMO: Extracorporeal membrane oxygenation; IABP: Intra-aortic balloon pump; LVEF: Left ventricular ejection fraction; SCr: Serum creatinine. Binary logistic regression analysis on risk factors of acute severe myocarditis patientsdeaths P < 0.05. BNP: Brain natriuretic peptide; CI: Confidence interval; cTnI: Cardiac troponin I; SCr: Serum creatinine. Comparison between acute nonsevere myocarditis group and acute severe myocarditis survival group ANSM: Acute nonsevere myocarditis; ASM: Acute severe myocarditis; BNP: Brain natriuretic peptide; cTnI: Cardiac troponin I; LVEF: Left ventricular ejection fraction; SCr: Serum creatinine.

Risk factors of death in adult patients with ASM

Single risk factor analysis: Compared with the ASM survival group, the duration of QRS complex, levels of cTnI, BNP, and SCr, and the incidence of the cardiogenic shock of patients in the ASM nonsurvival group were significantly increased (all P < 0.01). There was no statistical difference in basic characteristics, ST-T segment change of electrocardiogram, low left ventricular ejection fraction (LVEF), left ventricular enlargement, the incidence rate of major complications, and hospitalization length between the two groups (Table 1). Multivariate regression analysis: Binary logistic regression analysis revealed that the levels of SCr, cTnI, and BNP in the two groups were statistically different, which indicated that the abnormal increases of these three indicators were independent predictors for poor prognosis of patients with ASM (Table 2).
Table 2

Binary logistic regression analysis on risk factors of acute severe myocarditis patients’ deaths


Odds ratio
95%CI
P value
Cardiogenic shock2.6950.436-7.1830.361
QRS duration prolonged0.8510.426-1.6240.562
Increased SCr, > 100 pg/mL1.0431.013-1.0730.004a
Increased cTnI, > 3.1 ng/mL1.0551.000-1.1130.048a
Increased BNP, > 100 pg/mL0.9460.832-0.9930.024a

P < 0.05. BNP: Brain natriuretic peptide; CI: Confidence interval; cTnI: Cardiac troponin I; SCr: Serum creatinine.

Follow-up

There was no statistical difference in the follow-up duration between different groups. Two patients in the ASM survival group were readmitted to our department for treatment due to chest tightness and fatigue. They were diagnosed with DCM and improved after conservative treatment; one patient was readmitted for pacemaker implantation due to intermittent second-degree type II atrioventricular block within 1 year after discharge. One patient in the ANSM group was readmitted to our department due to chest tightness, palpitation, and increased cTnI. ANSM was diagnosed again, and the patient was discharged smoothly after conservative treatment; another patient was readmitted 4 years after discharge due to chest tightness, fatigue, and increased BNP and was diagnosed with dilated cardiomyopathy. There was no statistical difference between the readmission rate and the incidence rate of DCM between the two groups (Table 3).

DISCUSSION

Previous studies have shown that in patients presenting with mild symptoms and minimal ventricular dysfunction, myocarditis often resolves spontaneously without specific treatment, but there were also some patients whose condition deteriorated rapidly. Cardiogenic shock, malignant ventricular arrhythmia, cardiac arrest, and even death often occurred within a few days after diagnosis[1,2]. Myocarditis patients can have partial or full clinical recovery; some may relapse many years after the first episode. Relapses should be managed similarly to the index episode. For those who do not resolve, the disease may continue subclinically and lead to DCM[6]. At present, there is still a lack of reliable clinical indicators to predict the prognosis of ASM patients. A study revealed that indicators for poor prognosis included hypotension (blood pressure < 85/50 mmHg), high pulmonary capillary osmotic pressure, and application of mechanical ventilation, while sex, age, heart rate, cardiac output, creatine kinase peak value, and whether an intra-aortic balloon pump (IABP) was applied or not had no obvious influence on mortality[7]. Another study pointed out that patients with increased left ventricular diameter, decreased left ventricular systolic function, and gadolinium delayed enhancement in cardiac magnetic resonance (CMR) imaging have poor prognosis[8]. Studies concerned with the diagnosis of viral myocarditis by endometrial biopsy, immunohistochemistry, and polymerase chain reaction revealed that a cardiac function of NYHA Class III-IV and positive immunohistochemistry usually indicated a poor prognosis[9]. Recent studies have pointed out that systolic depression, left ventricular enlargement and low LVEF accompanied by acute renal failure and prolonged QRS complex were independent risk factors for poor prognosis of ASM patients[10-13]. Myocardial biopsy is of high value in predicting the early and long-term prognosis of myocarditis. We recommended that all patients with suspected myocarditis should undergo an EMB which is not a routine practice. Studies revealed that the prognosis of ASM with lymphocytic infiltration was worse than that with eosinophilic infiltration. There were statistically significant differences in all-cause mortality (37.5% vs 0%, P < 0.05) and cardiac mortality (31.2% vs 0%, P < 0.05)[3]. However, an invasive myocardial biopsy is still limited in clinical practice. Noninvasive imaging techniques such as CMR imaging can be useful in making the diagnosis of myocarditis and for monitoring disease progression, but we strongly endorse the concept that EMB should be the gold standard for the diagnosis of definite myocarditis[15,16]. This study found that patients in the ASM nonsurvival group and ASM survival group had significant differences in the intraventricular block (prolongation of QRS duration), SCr, cTnI, BNP value, cardiogenic shock, etc. However, there were no significant differences in sex, preinfection, ST-T segment change of the electrocardiogram, left ventricular enlargement, LVEF value, malignant arrhythmia, acute renal failure, incidence rate of antisynthetase syndrome, etc. Binary logistic regression analysis revealed that the elevated SCr, cTnI, and BNP values can be used as independent predictors of poor prognosis. The level of cTnI could reflect the degree of myocardial damage, and the increase of SCr value was a sensitive indicator for renal insufficiency. Cardiac insufficiency can cause hemodynamic abnormalities and promote the occurrence and development of renal insufficiency, which in turn can lead to water and sodium storage, electrolyte disturbance, acid-base imbalance, increased cardiac load, destroyed internal environment in which myocardial cells normally work, and formation of a vicious circle of cardiac and renal insufficiency. The occurrence of the above complications often indicates the aggravation of ASM. Another important finding of our research was that the appearance of aberrant occurrence conduct when patients had just been admitted to the hospital was closely related to the clinical death of patients. Of the 33 patients who died in this study, a total of eight patients developed a ventricular block, and all patients died of malignant ventricular arrhythmia and cardiac arrest eventually. We believed this could be caused by myocardial congestion, edema, and extensive myocardial injury, which reflected the severity of the disease. We recommend that temporary pacemakers, extracorporeal membrane oxygenation (ECMO), and IABP should be applied in time when aberrant ventricular conduction occurs. At present, there is no effective treatment for ASM. The major therapeutic strategies are myocardial nutrition, maintenance of water and electrolyte balance, conservative drug therapy, and immunosuppressive treatment. Furthermore, whether immunosuppressive therapy can effectively improve the prognosis of ASM patients is still controversial. Myocardial biopsy results confirmed that immunotherapy was effective in patients with eosinophilic myocarditis and giant cell myocarditis[17,18] but has no obvious effect on suspected or definite viral or lymphocytic myocarditis[19]. All ASM patients enrolled in this study were treated with a large dose of glucocorticoid (methylprednisolone 400-1000 mg/d). After 3 d of treatment, they were changed to oral prednisone and gradually reduced to discontinuation. In our study, due to the lack of comparison with the control group, it was difficult to make an objective and accurate evaluation on the curative effect of the hormone. However, we found that most patients’ symptoms were noticeably relieved after hormone application, and no obvious adverse reactions occurred. There is controversy about whether the application of immunoglobulin can effectively improve the prognosis of ASM patients at present[12,20], so we did not use immunoglobulin for patients. For ASM patients with severe hemodynamic disorder, cardiogenic shock, and pulmonary failure, the timely use of ECMO, IABP and other life-support equipment will help to eliminate the cardiopulmonary function. This will reduce the burden on the heart and lungs and help the patients to pass through the critical stage, which has significant curative effects on improving the prognosis and reducing mortality[21]. In this study, a total of five patients received ECMO implantation, in which two patients (40%) died eventually. This indicated that ECMO application had no significant difference in improving prognosis, which might be related to factors such as a small sample size included in this study and bias. Furthermore, we must realize that ASM is a self-limited disease. Patients in the severe stage can gradually enter the recovery period after 7-10 d of onset. However, the intermittent atrioventricular block, ventricular arrhythmia, left ventricular enlargement, LVEF reduction, and other conditions may be left after discharge from the hospital. Very few patients will develop DCM. The average follow-up time of patients in this study was 2 years. During this period, four patients in the ASM group and two patients in the ANSM group developed DCM. Due to the small sample size and short duration of follow-up in this study, the reason why ASM developed into DCM was still unclear. In the future, multicenter, large sample size, randomized controlled trials will be needed to explore the predictive value of various laboratory indicators on the prognosis of ASM.

CONCLUSION

Increased SCr, cTnI, and BNP value are independent risk factors for poor prognosis of ASM patients. Patients with an intraventricular block (prolonged QRS wave of electrocardiogram) have a higher mortality rate. The prognosis of ASM patients is generally good. Clinicians can classify patients with myocarditis according to their SCr, cTnI, and BNP value when they are admitted to the hospital to make clear the severity of their illness.

ARTICLE HIGHLIGHTS

Research background

Adult acute severe myocarditis (ASM) is acute in onset and severe in condition with different clinical manifestations and prognosis. After regular treatment, most patients with ASM had a good prognosis, but a few patients died of cardiogenic shock and malignant arrhythmia. Some patients developed dilated cardiomyopathy, third-degree atrioventricular block, and chronic arrhythmia after discharge.

Research motivation

A way to effectively assist clinicians in grading the severity of myocarditis patients when they are admitted to the hospital is urgently needed.

Research objectives

This retrospective study aimed to find the related factors influencing the early prognosis and analyze the results of follow-up in adult patients with acute fulminant myocarditis.

Research methods

Adult patients with acute myocarditis who came to our department from January 2014 to January 2020 were enrolled in this study. They were divided into two groups according to the degree of illness. The clinical symptoms, laboratory examination, treatment methods, complications, and the relationship between the treatment results of the two groups were retrospectively compared and discussed. The risk factors for death in patients with severe myocarditis were analyzed by binary logistic regression. A follow-up to 5.5 years was conducted on patients in the ASM survival group and acute nonsevere myocarditis group after discharge, and the readmission rate and incidence rate of dilated cardiomyopathy were analyzed.

Research results

A total of 265 patients, including 185 ASM and 80 acute nonsevere myocarditis patients were enrolled in our study. Of all the patients, 64.9% of patients (n = 172) were male with an average age of 39 ± 14-years-old. A total of 33 ASM patients (male, n = 20) died in the hospital with an average age of 40 ± 16-years-old. Compared with those in the survival group, the incidence of QRS wave duration, cardiac shock, serum creatinine (SCr) level, cardiac troponin I (cTnI) level, and brain natriuretic peptide (BNP) level significantly increased in the nonsurvival group. Furthermore, binary logistic regression analysis suggested that SCr, cTnI, and BNP levels were independently correlated with the prognosis in patients with fulminant myocarditis. No significant difference was found in the rehospitalization rate and the morbidity of dilated cardiomyopathy between the survival group and the nonsurvival group. In addition, adult patients with acute fulminant myocarditis discharged from the hospital have a good long-term prognosis.

Research conclusions

Increased SCr, cTnI, and BNP values are independent risk factors for poor prognosis of ASM patients. Clinicians can classify patients with myocarditis according to their SCr, cTnI, and BNP values when they are admitted to the hospital to make clear the severity of illness.

Research perspectives

So far, ASM developing to dilated cardiomyopathy is still unclear. Multicenter, large sample size, randomized controlled trials will be needed to explore the predictive value of various laboratory indicators on the prognosis of ASM.
  21 in total

1.  Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Alida L P Caforio; Sabine Pankuweit; Eloisa Arbustini; Cristina Basso; Juan Gimeno-Blanes; Stephan B Felix; Michael Fu; Tiina Heliö; Stephane Heymans; Roland Jahns; Karin Klingel; Ales Linhart; Bernhard Maisch; William McKenna; Jens Mogensen; Yigal M Pinto; Arsen Ristic; Heinz-Peter Schultheiss; Hubert Seggewiss; Luigi Tavazzi; Gaetano Thiene; Ali Yilmaz; Philippe Charron; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-07-03       Impact factor: 29.983

2.  Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives.

Authors:  Alida L P Caforio; Niall G Mahon; M Kamran Baig; Francesco Tona; Ross T Murphy; Perry M Elliott; William J McKenna
Journal:  Circulation       Date:  2006-12-18       Impact factor: 29.690

3.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology.

Authors:  Lisa Anderson; Dudley Pennell
Journal:  Eur Heart J       Date:  2008-05-02       Impact factor: 29.983

Review 4.  Update on myocarditis.

Authors:  Ingrid Kindermann; Christine Barth; Felix Mahfoud; Christian Ukena; Matthias Lenski; Ali Yilmaz; Karin Klingel; Reinhard Kandolf; Udo Sechtem; Leslie T Cooper; Michael Böhm
Journal:  J Am Coll Cardiol       Date:  2012-02-28       Impact factor: 24.094

Review 5.  The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy.

Authors:  Stephane Heymans; Urs Eriksson; Jukka Lehtonen; Leslie T Cooper
Journal:  J Am Coll Cardiol       Date:  2016-11-29       Impact factor: 24.094

6.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies.

Authors:  P Richardson; W McKenna; M Bristow; B Maisch; B Mautner; J O'Connell; E Olsen; G Thiene; J Goodwin; I Gyarfas; I Martin; P Nordet
Journal:  Circulation       Date:  1996-03-01       Impact factor: 29.690

Review 7.  Fulminant myocarditis.

Authors:  Fredric Ginsberg; Joseph E Parrillo
Journal:  Crit Care Clin       Date:  2013-07       Impact factor: 3.598

8.  Detailed pathologic evaluation on endomyocardial biopsy provides long-term prognostic information in patients with acute myocarditis.

Authors:  Jong-Chan Youn; Hyo Sup Shim; Jae Seok Lee; Ah-Young Ji; Jaewon Oh; Namki Hong; Hye Sun Lee; Sungha Park; Sang-Hak Lee; Donghoon Choi; Namsik Chung; Seok-Min Kang
Journal:  Cardiovasc Pathol       Date:  2014-01-17       Impact factor: 2.185

9.  [Risk factors for acute fulminant myocarditis in children].

Authors:  Xi-Chen Yang; Feng-Ming Wang; Nai-Zheng Zhao; Yu-Ming Qin
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2009-08

10.  A retrospective study: cardiac MRI of fulminant myocarditis in children-can we evaluate the short-term outcomes?

Authors:  Haipeng Wang; Bin Zhao; Haipeng Jia; Fei Gao; Junyu Zhao; Cuiyan Wang
Journal:  PeerJ       Date:  2016-12-15       Impact factor: 2.984

View more
  1 in total

1.  Prognosis Implication of N-Terminal Pro-B-Type Natriuretic Peptide in Adult Patients With Acute Myocarditis.

Authors:  Yan Zhao; Naqiang Lyu; Wei Zhang; Huiqiong Tan; Qi Jin; Aimin Dang
Journal:  Front Cardiovasc Med       Date:  2022-03-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.